PTPN11 - Wiki-Pi

Search Results for: PTPN11

Can't find the interaction you're looking for? Try the advanced search

174 interactions involving PTPN11 - protein tyrosine phosphatase non-receptor type 11 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases

Symbol	Description	Pathways Hide	Drugs Hide	Diseases Hide
MAPK3	mitogen-activated protein kinase 3	MAPK3 (ERK1) activation RAF-independent MAPK1/3 activation ISG15 antiviral mechanism Signaling by NODAL Spry regulation of FGF signaling Signaling by Activin Frs2-mediated activation ERK/MAPK targets ERK/MAPK targets ERKs are inactivated Regulation of actin dynamics for phagocytic cup formation Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Oncogene Induced Senescence FCERI mediated MAPK activation Regulation of HSF1-mediated heat shock response NCAM signaling for neurite out-growth RSK activation Signal transduction by L1 Activation of the AP-1 family of transcription factors Thrombin signalling through proteinase activated receptors (PARs) Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate NADPH Oxidases RAF/MAP kinase cascade MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RNA Polymerase I Promoter Opening Signal attenuation Interferon gamma signaling Advanced glycosylation endproduct receptor signaling Gastrin-CREB signalling pathway via PKC and MAPK ESR-mediated signaling RUNX2 regulates osteoblast differentiation Regulation of PTEN gene transcription Regulation of the apoptosome activity Estrogen-dependent nuclear events downstream of ESR-membrane signaling Suppression of apoptosis Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants FCGR3A-mediated phagocytosis Nuclear events stimulated by ALK signaling in cancer IFNG signaling activates MAPKs Negative Regulation of CDH1 Gene Transcription NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes Growth hormone receptor signaling Signaling by LTK in cancer Transcriptional and post-translational regulation of MITF-M expression and activity	Sulindac Acetylsalicylic acid Minocycline Arsenic trioxide Colforsin Purvalanol 5-iodotubercidin Seliciclib Cholecystokinin Ulixertinib
MAPT	microtubule associated protein tau	Caspase-mediated cleavage of cytoskeletal proteins	Lansoprazole Astemizole Paclitaxel Docetaxel Flortaucipir F-18	Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3) Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
MET	MET proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels Drug-mediated inhibition of MET activation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Sunitinib K-252a SGX-523 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol AMG-208 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Capmatinib Tivozanib Fostamatinib Tivantinib Brigatinib Amuvatinib Tepotinib Amivantamab	Cholangiocarcinoma Gastric cancer Renal cell carcinoma
MPIG6B	megakaryocyte and platelet inhibitory receptor G6b	GPVI-mediated activation cascade
MPL	MPL proto-oncogene, thrombopoietin receptor	Platelet Aggregation (Plug Formation)	Romiplostim SB-559448 Eltrombopag Thrombopoietin Avatrombopag Lusutrombopag	Congenital amegakaryocytic thrombocytopenia (CAMT)
MPZL1	myelin protein zero like 1
MS4A2	membrane spanning 4-domains A2	Fc epsilon receptor (FCERI) signaling Fc epsilon receptor (FCERI) signaling Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization FCERI mediated NF-kB activation	Omalizumab	Asthma
MVP	major vault protein	Neutrophil degranulation
NEB	nebulin	Striated Muscle Contraction		Distal muscular dystrophies, including: Welander distal myopathy (WDM); Tibial muscular dystrophy (TMD); Nonaka distal myopathy with rimmed vacuoles (DMRV); Miyoshi myopathy (MM); Laing myopathy (MPD1); Distal nebulin myopathy (DNM); Distal desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Distal myotilinopathy (MFM3); Distal zaspopathy (MFM4); Distal myopathy 3 (MPD2, VCPDM) Nemaline myopathy
NEDD9	neural precursor cell expressed, developmentally down-regulated 9
NOX4	NADPH oxidase 4	Detoxification of Reactive Oxygen Species STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins
NSUN5	NOP2/Sun RNA methyltransferase 5
NSUN5P2	NSUN5 pseudogene 2
NTRK1	neurotrophic receptor tyrosine kinase 1	PLC-gamma1 signalling Signalling to RAS ARMS-mediated activation ARMS-mediated activation Retrograde neurotrophin signalling Retrograde neurotrophin signalling NGF-independant TRKA activation TRKA activation by NGF TRKA activation by NGF Signalling to p38 via RIT and RIN PI3K/AKT activation PI3K/AKT activation Signalling to STAT3	Amitriptyline Imatinib Regorafenib Entrectinib Fostamatinib Cenegermin Larotrectinib Pralsetinib	Neuroblastoma Thyroid cancer
NTRK2	neurotrophic receptor tyrosine kinase 2	PIP3 activates AKT signaling NGF-independant TRKA activation Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling BDNF activates NTRK2 (TRKB) signaling NTF3 activates NTRK2 (TRKB) signaling NTF4 activates NTRK2 (TRKB) signaling Activated NTRK2 signals through RAS Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PI3K Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FYN NTRK2 activates RAC1 NTRK2 activates RAC1 Activated NTRK2 signals through CDK5	Amitriptyline Esketamine Entrectinib Fostamatinib Larotrectinib	Neuroblastoma
ORMDL3	ORMDL sphingolipid biosynthesis regulator 3	Sphingolipid de novo biosynthesis Neutrophil degranulation
PAG1	phosphoprotein membrane anchor with glycosphingolipid microdomains 1	GAB1 signalosome Phosphorylation of CD3 and TCR zeta chains
PDGFRA	platelet derived growth factor receptor alpha	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Imatinib-resistant PDGFR mutants Sunitinib-resistant PDGFR mutants Regorafenib-resistant PDGFR mutants Sorafenib-resistant PDGFR mutants PDGFR mutants bind TKIs	Becaplermin Imatinib Sunitinib XL820 Olaratumab Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin keratinocyte (neonatal) Tivozanib Fostamatinib Erdafitinib Amuvatinib Ripretinib	Glioma
PDGFRB	platelet derived growth factor receptor beta	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Becaplermin Sorafenib Imatinib Dasatinib Sunitinib XL999 XL820 Pazopanib Midostaurin Regorafenib Nintedanib Polaprezinc Trapidil Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Erdafitinib Pexidartinib Ripretinib Pralsetinib	Glioma
PECAM1	platelet and endothelial cell adhesion molecule 1	Platelet degranulation Cell surface interactions at the vascular wall PECAM1 interactions Integrin cell surface interactions Platelet sensitization by LDL Neutrophil degranulation High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells

Page 6 out of 9 pages